[China Cord Blood Corporation 48th Floor, Bank of China Tower 1 Garden Road, Central Hong Kong S.A.R. , October 31 John Reynolds Re: China Cord Blood Corporation Registration Statement on Form F-3 File No. 333-191121 Dear Mr. Reynolds: Very truly yours, China Cord Blood Corporation Albert Chen Albert Chen Chief Financial Officer CORRESP 1 filename1.htm]
[Chinard Bloodrporation 48th Floor, Bank of China Tower 1 Garden Road, Central Hong KongR. , October 31 John Reynolds Re: Chinard Bloodrporation Registration Statement on Form F-3 File No. 333-191121 Dear Mr. Reynolds: Very truly yours, Chinard Bloodrporationbert Chenbert Chen Chief Financial Officer]
[Chinard Bloodrporation 48th Floor, Bank of China Tower 1 Garden Road, Central Hong KongR. , October 31 John Reynolds Re: Chinard Bloodrporation Registration Statement on Form F-3 File No. 333-191121 Dear Mr. Reynolds: Very truly yours, Chinard Bloodrporationbert Chenbert Chen Chief Financial Officer]
[Subject to completion, dated October 30, 2013 PROSPECTUS $100,000,000 CHINA CORD BLOOD CORPORATION Ordinary Shares The securities covered by this prospectus may be offered and sold from time to time in one or more offerings, which may be through one or more underwriters, dealers and agents, or directly to the purchasers. The names of any underwriters, dealers or agents, if] [Three Months Ended Year Ended March 31, 2013 2013 2012 2011 2010 2009 Ratio of earnings to fixed charges 2.5 3.2 27.6 30.6 19.2 30.1 Earnings: Three Months Ended Year Ended March 31, RMB’000 2013 2013 2012 2011 2010 2009 Income before income tax 44,432 158,185 151,599 132,142 79,663 42,299 Add: Fixed charges Interest expense 14,758] [Consent of Independent Registered Public Accounting Firm The Board of Directors China Cord Blood Corporation We consent to the use of our reports dated July 31, 2013, with respect to the consolidated balance sheets of China Cord Blood Corporation and subsidiaries as of March 31, 2012 and 2013, and the related consolidated statements of comprehensive income, changes in equity, and]
[Subject to completion, dated October 30, 2013 PROSPECTUS $100,000,000 CHINA CORD BLOOD CORPORATION Ordinary Shares The securities covered by this prospectus may be offered and sold from time to time in one or more offerings, which may be through one or more underwriters, dealers and agents, or directly to the purchasers. The names of any underwriters, dealers or agents, if] [Three Months Ended Year Ended March 31, 2013 2013 2012 2011 2010 2009 Ratio of earnings to fixed charges 2.5 3.2 27.6 30.6 19.2 30.1 Earnings: Three Months Ended Year Ended March 31, RMB’000 2013 2013 2012 2011 2010 2009 Income before income tax 44,432 158,185 151,599 132,142 79,663 42,299 Add: Fixed charges Interest expense 14,758] [Consent of Independent Registered Public Accounting Firm The Board of Directors China Cord Blood Corporation We consent to the use of our reports dated July 31, 2013, with respect to the consolidated balance sheets of China Cord Blood Corporation and subsidiaries as of March 31, 2012 and 2013, and the related consolidated statements of comprehensive income, changes in equity, and]
[Subject tompletion,ted October 30, 2013 PROSPECTUS $100,000,000 CHINARD BLOODRPORATION Ordinary Shares The securitiesvered by this prospectus may be offered and sold from time to time in one or more offerings, which may be through one or more underwriters, dealers andents, or directly to the purchasers. The names of any underwriters, dealers orents, if any, will] [Three Months Ended Year Ended March 31, 2013 2013 2012 2011 2010 2009 Ratio of earnings to fixed charges 2.5 3.2 27.6 30.6 19.2 30.1 Earnings: Three Months Ended Year Ended March 31, RMB000 2013 2013 2012 2011 2010 2009ome beforeome tax 44,432 158,185 151,599 132,142 79,663 42,299d: Fixed charges] [Consent of Independent Registered Public Accounting Firm The Board of Directors Chinard Bloodrporation Wensent to the use of our reportsted July 31, 2013, with respect to thensolidated balance sheets of Chinard Bloodrporation and subsidiaries of March 31, 2012 and 2013, and the relatednsolidated statements ofmprehensiveome, changes in equity, andsh flows for each of the years]
[Subject tompletion,ted October 30, 2013 PROSPECTUS $100,000,000 CHINARD BLOODRPORATION Ordinary Shares The securitiesvered by this prospectus may be offered and sold from time to time in one or more offerings, which may be through one or more underwriters, dealers andents, or directly to the purchasers. The names of any underwriters, dealers orents, if any, will] [Three Months Ended Year Ended March 31, 2013 2013 2012 2011 2010 2009 Ratio of earnings to fixed charges 2.5 3.2 27.6 30.6 19.2 30.1 Earnings: Three Months Ended Year Ended March 31, RMB000 2013 2013 2012 2011 2010 2009ome beforeome tax 44,432 158,185 151,599 132,142 79,663 42,299d: Fixed charges] [Consent of Independent Registered Public Accounting Firm The Board of Directors Chinard Bloodrporation Wensent to the use of our reportsted July 31, 2013, with respect to thensolidated balance sheets of Chinard Bloodrporation and subsidiaries of March 31, 2012 and 2013, and the relatednsolidated statements ofmprehensiveome, changes in equity, andsh flows for each of the years]
[EXPLANATORY NOTE Th Description 99.1* Press Release,ted August 26, 2013 101.INS XBRL Instance Document 101.SCH XBRL Taxonomy Extensionhema Document 101.CAL XBRL Taxonomy Extensionlculation Linkbase Document 101.LAB XBRL Taxonomy Extension Label Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document * Previously filed. CHINARD BLOODRPORATIONbert Chen]
[EXPLANATORY NOTE Th Description 99.1* Press Release,ted August 26, 2013 101.INS XBRL Instance Document 101.SCH XBRL Taxonomy Extensionhema Document 101.CAL XBRL Taxonomy Extensionlculation Linkbase Document 101.LAB XBRL Taxonomy Extension Label Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document * Previously filed. CHINARD BLOODRPORATIONbert Chen]
